Real-world data from the use of ranolazine in patients with stable angina pectoris: the RANGER study

Abstract Background Although ranolazine is available since years as a second-line treatment to reduce angina attacks in patients with stable pectoris, real-world data on effectiveness, tolerability and safety of are limited. Methods A non-interventional, prospective study conducted assess the effectiveness ranolazine. Patients eligible for enrolment had baseline assessment between one fourteen days after initiating first time follow-up visit three months later. Primary endpoints comprised weekly frequency attacks, total adverse events discontinuation rate. Secondary included use short-acting nitrates, changes Canadian Cardiovascular Society (CCS) classification score quality life scale (QoL). Results In total, 1,101 were enrolled 214 sites. Mean reduced from 3.6±2.9 0.4±0.9 (p<0.0001) mean consumption nitrates decreased by 1.7±2.2 (p<0.0001). CCS class QoL also improved Adverse reported 11 (1%) totally, while 2 them (0.2%) characterized serious. Treatment was discontinued any reason 23 (2.1%) period. Ranolazine equally effective all subgroups tested, larger benefits observed more frequent III IV. Up-titration during outcomes. Conclusion well-tolerated effectively simultaneous improvement angina. Funding Acknowledgement Type funding sources: Private company. Main source(s): The sponsored Menarini Hellas. sponsor involved concept design interpretation this publication, but not collection analysis. Hellas funded medical writing support publication.